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Purpose: This study was undertaken to define the long-term effects of renal revascularization on blood pressure, and renal
and cardiac function in patients with Takayasu arteritis–induced renal artery stenosis (TARAS).
Methods: Twenty-seven patients (25 women; mean age, 27 years) with TARAS underwent intervention. Primary, primary
assisted, and secondary patency rates were determined, and the late effects on blood pressure, renal and cardiac function,
and survival were analyzed.
Results: All patients had hypertension (mean blood pressure, 167/99 mm Hg; 2.5 antihypertensive medications per
patient). Mean estimated glomerular filtration rate in patients not receiving hemodialysis was 76 mL/min, and in five
patients serum creatinine concentration was greater than 1.5 mg/dL. Three patients were hemodialysis-dependent, and
two had intractable congestive heart failure. Forty interventions were performed, including 32 aortorenal bypass
procedures, two repeat implantations, four nephrectomies, and two transluminal angioplasty procedures. Postoperative
morbidity was 19%. There were no deaths. During follow-up (mean, 68 months), three graft stenoses, all due to intimal
hyperplasia, and three graft occlusions occurred. Two of three graft stenoses were successfully revised. At 1, 3, and 5 years
of follow-up, primary patency was 87%, 79%, and 79%, respectively; primary assisted patency was 93%, 89%, 89%,
respectively; and secondary patency was 93%, 89%, and 89%, respectively. Intervention resulted in a decrease in blood
pressure to a mean of 132/79 mm Hg (P < .0001), and the need for antihypertensive medications was reduced to one per
patient (P < .01). Mean glomerular filtration rate increased to 88 mL/min (P < .005), and two patients no longer
required hemodialysis. Congestive heart failure resolved in both patients, and did not recur. There were three deaths
during follow-up, with 5-year and 10-year actuarial survival of 96% and 80%, respectively.
Conclusions: Renal revascularization to treat TARAS is durable, has a salutary effect on blood pressure, and enhances
long-term renal and cardiac function. This response establishes renal revascularization as a successful and durable
intervention for TARAS, and a benchmark to which other therapies should be compared. (J Vasc Surg 2004;39:749-57.)Takayasu arteritis (TA) is a nonspecific granulomatous
inflammatory arteriopathy of unknown cause that results in
occlusive obliteration or less commonly aneurysm degen-
eration of large and medium-sized elastic arteries. The
disease was first described in 1908 by Takayasu,1 a Japanese
ophthalmologist, in a young female patient with retinal
neovascularization and absent radial pulses. Subsequent
descriptions of the disease have emphasized the “pulseless”
syndrome, with involvement of the brachiocephalic arter-
ies. However, less attention has been paid to involvement
of other segments of the aorta, the visceral arteries, and in
particular the renal arteries. Unrecognized TA-induced
renal artery stenosis (TARAS) can result in malignant hy-
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doi:10.1016/j.jvs.2003.12.022pertension, severe renal dysfunction, cardiac decompensa-
tion, and premature death.2 The morbidity associated with
delayed diagnosis requires greater awareness, and more
aggressive diagnostic evaluation and treatment in patients
with TARAS.
In 1990 we reported our initial experience with TA,3
focusing on the beneficial effects of surgical revasculariza-
tion in a variety of anatomic locations in appropriately
selected patients. The present study was undertaken to
evaluate the outcome of intervention specifically for
TARAS, with emphasis on the long-term effects of revas-
cularization on blood pressure, renal function, cardiac
function, and survival.
METHODS
Between 1977 and 2003, 27 patients with TARAS
received treatment at the Keck School of Medicine of the
University of Southern California. The diagnosis of TA was
established by the presence of at least three criteria, as
outlined by the American College of Rheumatology4: age
at onset younger than 40 years, extremity claudication,
decreased brachial artery pulse, differential of greater than
10 mm Hg in upper extremity systolic pressure, subclavian
or abdominal aortic bruit, and focal angiographic aortic or
branch vessel abnormality. Patient demographic data, use
of steroid or immunosuppressant agents, erythrocyte sedi-749
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ment and previous vascular procedures; preoperative blood
pressure (BP), number of antihypertensive medications,
serum creatinine concentration (SCr), cardiac function,
and angiographic and computed tomography (CT) find-
ings; procedures performed at our center, associated 30-
day morbidity and mortality; postoperative BP, SCr, car-
diac function, graft patency, and mortality were collected
through review of patient records and imaging studies.
Primary study end points were comparison of preoper-
ative BP and medication requirements, estimated glomer-
ular filtration rate (GFR), SCr, cardiac function, and mor-
phologic features with those documented at last follow-up;
patency of the renal revascularization; and patient survival.
BP was obtained with a sphygmomanometer in the
office or hospital setting in a limb clinically free of or least
involved with TA. Hypertension was defined as systolic BP
greater than 140 mm Hg or diastolic BP greater than 90
mm Hg,5 or current use of antihypertensive medications.
Renal function was determined with the SCr concentration
(mg/dL), and estimated GFR with the Cockcroft-Gault
method.6 Renal dysfunction was defined as SCr 1.5 mg/dl
or greater,7 or the need for hemodialysis. Congestive heart
failure was diagnosed with the Framingham clinical crite-
ria.8 Left ventricular hypertrophy (LVH) was documented
with transthoracic echocardiography as an increased wall
mass index.9
Aortography that included the ascending aorta, aortic
arch, and descending and abdominal aorta was performed
in all patients before surgical or endovascular intervention.
When aortograms suggested significant longitudinal aortic
involvement, such as patent but irregular aortic contour,
CT with intravenous contrast medium was performed to
define the extent of aortic wall thickening. This information
was used along with the intraoperative findings to locate
the aortic anastomosis in the least diseased aortic segment.
Unilateral renal revascularization was accomplished
through a subcostal incision and a retroperitoneal ap-
proach. Simultaneous bilateral renal revascularization was
achieved through a midline incision and transperitoneal
exposure. A left seventh interspace thoracoabdominal ap-
proach was reserved for patients with concomitant thoracic
Table I. Patient characteristics
Parameter n %
Sex
Female 25 (93)
Male 2 (7)
Race
Asian 5 (19)
White 4 (15)
Hispanic 18 (67)
Age at diagnosis (y)
(mean  SEM)
27  2.5
Follow-up (mo)
Mean 68
Range 1-154aortic involvement that required repair. Revascularization
was accomplished in most cases with bypass grafts. Autog-
enous saphenous vein was the preferred graft, with pros-
thetic grafts and hypogastric artery reserved for patients
without suitable vein. The aorta or an aortic branch vessel
with minimal inflammatory involvement, or an aortic graft
when present, was used for graft inflow. Distal graft anas-
tomoses were placed in grossly normal renal artery distal to
the inflammatory process. Ex vivo techniques were used in
kidneys with significant branch vessel involvement. Ne-
phrectomy was performed when extensive inflammatory
involvement of the renal artery precluded vascular recon-
struction. Renal revascularization was followed by serial
duplex ultrasound scanning, magnetic resonance angiogra-
phy, or aortography in all patients. In patients with sus-
pected occlusion or stenosis at noninvasive imaging, aor-
tography was performed for confirmation.
Use of data from patient charts for purposes of this
study was approved by the institutional review board. Con-
tinuous variables are expressed as mean  SEM, and mean
values were compared with paired two-tailed Student t
tests. Significance was attributed at P  .05. Patency rates
for revascularization were based on postoperative serial
imaging studies and confirmation aortograms. Patency
rates and patient survival were estimated with life table
analysis.
RESULTS
Patient demographic data are shown in Table I. Ninety-
three percent of patients were women, and 67% were
Hispanic. All patients had received steroid therapy for TA at
some point in the course of the disease, and 13 were
receiving steroid therapy at the time of intervention. Im-
munosuppression with cyclosporine or methotrexate had
been used in 14 patients. Two patients were receiving
methotrexate, one was receiving cyclosporine, and one was
receiving azathioprine at the time of renal revascularization.
Eight patients had previously undergone 11 renal interven-
tions at outside facilities, including seven percutaneous
angioplasty procedures, three aortorenal bypass proce-
dures, and one nephrectomy. All revascularizations had
failed. Fourteen patients had undergone interventions in
nonrenal vascular beds, including three ascending aortic
replacements, three aortocarotid bypass procedures, three
aortoiliofemoral bypass procedures, two cardiac valve re-
placements, and one carotid-subclavian bypass procedure.
Pre-intervention ESR was 26.2  5.1 mm/h (range,
4-114 mm/h), and in 12 patients ESR was greater than 10
mm/hr at the time of intervention. At presentation, all 27
patients had hypertension, with BP 167  6/99  5 mm
Hg, requiring 2.5  0.3 medications per patient. Three
patients were dialysis-dependent. In the remaining 24 pa-
tients mean SCr was 1.2 0.1 mg/dL, and estimated GFR
was 76  4.5 mL/min. In five of the 24 patients SCr was
greater than 1.5 mg/dL. LVH was documented in 16
patients, and refractory congestive heart failure secondary
to systolic ventricular dysfunction in two patients. Aortog-
raphy demonstrated focal occlusive renal artery disease
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dilatation in two patients. Eleven renal arteries were oc-
cluded, and the remainder were stenotic. The descending
thoracic aorta was involved in two patients, and the femoral
arteries in three patients.
Thirty-six kidneys were revascularized. Renal revascu-
larization was accomplished with use of bypass grafts in 32
kidneys, renal artery reimplantation in two kidneys, and
percutaneous transluminal angioplasty in two kidneys. Or-
igin of the bypass grafts was the infrarenal aorta in 19
patients, an aortic graft in five, the suprarenal abdominal
aorta in four, the thoracic aorta in two, and a visceral artery
in two. Bypass grafts were autogenous (19 saphenous vein,
one hypogastric artery) in 20 patients, and prosthetic in 12
patients. Renal branch vessel reconstruction was required in
five bypass procedures, with one requiring ex vivo tech-
nique. Four nephrectomies were performed, two at the
time of contralateral renal revascularization, one before
contralateral revascularization, and one as the sole proce-
dure. Five aortic reconstructions and one inferior mesen-
teric artery reimplantation were also performed at the time
of revascularization. Postoperative morbidity (19%) in-
cluded wound infection (n 2), myocardial infarction (n
1), retroperitoneal hematoma requiring repeat exploration
(n  1), and mesenteric ischemia requiring superior mes-
enteric artery revascularization (n  1). There were no
postoperative deaths.
Mean follow-up was 68  9 months (range, 3-154
months). Long-term steroid therapy was maintained in
seven patients, and immunosuppressant therapy in one
patient. During postoperative follow-up, three (8%) graft
stenoses were documented, at 4, 9, and 29 months, respec-
tively (mean, 14 months), and three (8%) graft occlusions
occurred, at 3, 3, and 32 months, respectively (mean, 13
months). The six graft failures occurred in five patients. At
the time of graft failure, two patients were receiving steroid
therapy and three were not receiving any therapy. Two
stenoses and two occlusions occurred in prosthetic grafts,
and one each in autogenous grafts. Graft stenoses were
successfully revised with percutaneous angioplasty in one
patient, and surgical revision of a distal anastomotic steno-
Fig 1. Primary patency (graft patency without intervention), with
95% confidence intervals, by life table analysis, after revasculariza-
tion to treat Takayasu arteritis–induced renal artery stenosis. Num-
bers represent number of patent grafts followed up at each time
point. Patency at 1, 3, and 5 years was 87%, 79%, and 79%,
respectively.sis in the second patient. The third graft was replaced with
a prosthetic aortorenal graft. In both surgical interventions,
histopathologic examination of the stenosis showed intimal
hyperplasia without any evidence of arteritis. All three
patients had normal renal function and well-controlled BP
at last follow-up.
There were three graft occlusions in two patients. One
patient was receiving hemodialysis at the time of the origi-
nal procedure. The revascularization was remarkable for
extensive inflammatory involvement of both renal arteries,
which made branch vessel reconstruction necessary. After
occlusion of both grafts, further revascularization was not
attempted. The patient continued to require hemodialysis,
and died of complications of renal failure 9 months after
surgical intervention. In the other patient, repeat revascu-
larization with splenorenal bypass was successful, but even-
tually renal failure developed, and the patient died 9 years
after the initial procedure, of a cardiac event. Primary
patency of the renal revascularization at 1, 3, and 5 years
was 87%, 79%, and 79%, respectively (Fig 1). The corre-
sponding primary assisted patency rates were 93%, 89%, and
89%, respectively, and secondary patency rates were 93%,
89% and 89%, respectively (Fig 2; Tables II-V, online only).
At last follow-up, mean BP had decreased to 132 
4/79  2 mm Hg (P  .01), and the requirement for
antihypertensive medications was reduced to 1 0.2 drugs
per patient (P .01). Ten patients had normal BP without
any antihypertensive medications, two patients had no im-
provement in BP or change in medication requirements,
and the remaining 15 patients improved (BP, 140/90,
with decreased medication requirements). In the 24 pa-
tients who were not dialysis-dependent preoperatively, SCr
decreased to 1 0.1 mg/dL (P .05), and estimated GFR
improved to 88  5 mL/min (P  .05). In all but two
patients SCr was less than 1.5 mg/dL. Two of three dialy-
sis-dependent patients no longer required hemodialysis.
Preoperative and postoperative echocardiograms were
available for 21 patients for comparison. Documented re-
gression of LVH occurred in nine patients (33%), and
hypertrophy developed in two patients (7%) during follow-
Fig 2. Primary assisted patency (graft patency including revised
patent but stenotic grafts) and secondary patency (graft patency
including revised stenotic and occluded grafts, with 95% confi-
dence intervals, by life table analysis, after revascularization to treat
Takayasu arteritis–induced renal artery stenosis. Numbers repre-
sent number of patent grafts followed up at each time point.
Patency at 1, 3, and 5 years was 93%, 89%, and 89%, respectively.
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did not recur.
Of the 27 patients who underwent treatment of
TARAS, 14 (52%) continue to be followed; 10 patients
(37%) were lost to follow-up, at a mean of 70 11 months;
and three patients (11%) died. Three patients had uncom-
plicated pregnancies and childbirth after successful revascu-
larization. Two patients with failed interventions died, as
described above, and a third patient died 14 years after
successful revascularization, as a result of a transfusion
reaction. Actuarial survival at 5 and 10 years was 96% and
80%, respectively (Fig 3).
DISCUSSION
Published information concerning the long-term out-
come of renal revascularization to treat TARAS comes from
India, the Far East, and France. These reports vary consid-
erably in their focus, may or may not define the criteria used
to diagnose TARAS, often do not analyze separately the
results of intervention for TARAS and interventions in
other arterial beds, and analyze only the outcomes of BP
and renal artery or graft patency.
Data regarding endovascular renal procedures to treat
TARAS are limited, with only three studies of any size, all
from India.10-12 In one study of 20 patients who under-
went 33 angioplasty procedures to treat TARAS, Sharma et
al10 reported a technical success rate of 85%, with clinical
BP improvement in 82%. Selective angiographic follow-up
at a mean of 8 months demonstrated recurrent stenosis in
21%. A follow-up experience from Sharma et al11 described
the results in 62 patients with TARAS. Immediate technical
success and positive BP response was 95% and 89%, respec-
tively. Cure of hypertension was demonstrated in 23% of
patients. Mean follow-up was 22 months, and a recurrent
stenosis rate of 16% was angiographically documented in
patients with recurrent hypertension. The degree of BP
response is not provided, and discussion of renal function
and cardiac function is not included. Tyagi et al12 studied
54 patients with 75 renal lesions from TARAS. An 89%
technical success rate was reported, and a 14% recurrent
stensois rate was documented at 14 months of follow-up.
Reported results of surgical revascularization to treat
TARAS have, for the most part, focused on the use of
Fig 3. Patient survival, with 95% confidence intervals, by life table
analysis, after revascularization to treat Takayasu arteritis–induced
renal artery stenosis. Numbers represent number of patients fol-
lowed up at each time point. Survival at 5 and 10 years was 96% and
80%, respectively.bypass grafts, inasmuch as the transmural injury of TA does
not lend itself to endarterectomy or open angioplasty.13
Keiffer et al14 reported surgical revascularization of 37 renal
arteries in 24 patients. Ancillary procedures such as aortic
reconstruction (87%) and visceral revascularization (71%)
were common. There was one postoperative death. At a
mean follow-up of 61.3 months, hypertension was cured in
12 patients (63%) and improved in 31%. Remedial renal
revascularization was required in four patients during fol-
low-up. Two other series, one by Lagneau et al13 and the
other by Pokrovsky et al,15 report similar surgical success,
with hypertension cured in 55% to 63% of patients and
improved in 17% to 45%, at follow-up of 5 to 14 years. As
with endovascular therapy, the end points of renal function
and cardiac function were not studied.
Given the beneficial effects we previously reported for
surgical revascularization in TA,3 we have preferentially
treated TARAS with open surgical techniques. However,
one patient in our current series did undergo successful
staged bilateral angioplasty and has required no further
intervention. Angioplasty was used in this patient because
of her young age, relatively early onset of TARAS with
stabilization with steroid therapy, and some regression of
renal stenosis. The first angioplasty procedure was per-
formed when the patient was 13 years of age, and the
second a year later. Medical management has included
prednisone and methotrexate, and the patient is now 20
years old, without evidence of recurrent stenosis. In con-
trast, seven other angioplasty procedures performed at out-
side institutions before surgical revascularization failed, and
one resulted in loss of a kidney.
On the basis of our limited experience and that dis-
cussed above, it appears that the results of endovascular
therapy can be optimized when TARAS is limited and
somewhat reversible with medical therapy. Longstanding,
chronic TA, the most common clinical scenario seen at our
institution, produces full-thickness vessel injury, an inelas-
tic fibrotic arterial wall, and a significant incidence of occlu-
sion. Renal artery occlusion was documented in 30% of the
patients reported by Lagneau et al,13 and a similar percent-
age was noted in our study. Both factors, the pathologic
findings and rate of occlusion, limit the use of angioplasty.
Whether the advances in endovascular technology, includ-
ing the use of stents in the renal position, will expand the
indications for endovascular treatment of TARAS, as it has
for atherosclerotic disease, remains to be established.
Inherent to any discussion of surgical treatment of
TARAS is the natural history of TA and the role of medical
management. In previous reports concerns have been ex-
pressed that intervention for TA before or without medical
therapy may compromise the surgical results16 because of
progression of the inflammatory process. In the present
study, approximately 50% of patients were receiving steroid
or immunosuppressant therapy at the time of operation,
and 35% were maintained on therapy long term. Neverthe-
less, graft failure was uncommon and as likely to occur in
patients receiving therapy as those not receiving medical
therapy. Our findings are consistent with two reports from
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durability of vascular reconstructions performed to treat
symptomatic TA.17,18 However, in both reports the specif-
ics of the postoperative medical therapy are not provided.
The natural history most consistent with the foregoing
observations is that segmental injury to the aorta and its
branches from TA is a one-time insult of unknown cause.
This ultimately results in fibrous obliteration and stenosis,
and at times superimposed atherosclerosis of the affected
arterial segments. In this context the primary and greatest
benefit of medical therapy is to limit the arterial inflamma-
tion in involved segments, particularly early in the disease.
How much benefit this provides over time and whether it
justifies the long-term use of immunosuppressant and cor-
ticosteroid therapy is unknown. Furthermore, the absence
of reliable biochemical markers, such as ESR, C-reactive
protein, and von Willebrand factor, to determine the acuity
of the inflammatory process19 means that the indications
for medical therapy are inexact and empirically based on
patient symptoms and elevated inflammatory markers.
However, medical therapy does not eliminate, should not
delay, and cannot be used in place of renal revascularization
in the patient with TARAS complicated by malignant hy-
pertension, renal dysfunction, or cardiac decompensation.
With these assumptions in mind, renal revasculariza-
tion was performed in patients with TARAS, and provided
1, 3, and 5-year patency rates similar to those reported by
others for TARAS and approaching those reported for
fibromuscular dysplasia20 and atherosclerosis.21 Concomi-
tant aortic reconstruction or suprarenal location for inflow
was often necessary to avoid an infrarenal aorta with exten-
sive TA involvement. Mesenteric revascularization was
rarely required in the absence of clinical symptoms of
mesenteric ischemia. The type of renal bypass graft used did
not appear to influence the results, because late failures
occurred with both autogenous and prosthetic grafts.
Previous studies of surgical revascularization for TA
have documented graft failures secondary to inflammatory
involvement at anastomoses. Consequently, we altered our
operative technique in the mid-1980s so that all anastomo-
ses are placed in macroscopically normal aorta or renal
artery segments, or, in the absence of that possibility,
segments with minimal TA involvement. For location of
the aortic anastomosis a preoperative contrast-enhanced
CT scan can be helpful in identifying which aortic segment
has the least mural thickening from TA. On occasion,
because of diffuse mural abdominal aortic involvement,
optimal aortic inflow requires concomitant aortic recon-
struction or a suprarenal or thoracic aortic anastomosis. In
addition, placing the distal anastomosis in normal renal
artery may require extensive dissection of the segmental
branches of the kidney, branch reconstruction, and ex vivo
techniques. Since adoption of the above surgical approach
we have not observed progression of TA to cause graft
failure in any patient with TARAS or in patients with TA
with failed extrarenal reconstructions.3 Rather, the patho-
logic features of explanted failed grafts are typical of the
intimal hyperplasia found in failed vascular reconstructionsperformed to treat atherosclerotic occlusive disease. Fur-
thermore, unlike the experience of Miyata et al,22 who
reported an 8.5% incidence of anastomotic aneurysm in
103 patients with surgically treated TA, anastomotic aneu-
rysms did not occur in our patients. However, those au-
thors reported that 25% of TA lesions they treated were
aneurysms, compared with only 7% in our series. They also
documented that aneurysmal TA is an independent predic-
tor for the development of an anastomotic aneurysm.
The decision to proceed with revascularization was
predicated on the angiographic findings of an occluded or
stenotic (60%) renal artery from TARAS in a patient with
hypertension. Associated renal or cardiac dysfunction was
also considered when making the decision to proceed with
revascularization. Functional tests such as renal vein renin
assays or captopril renography were not routinely used to
determine the appropriateness of revascularization. Ne-
phrectomy was performed only for kidneys that at operative
exploration had nonreconstructible renal anatomy. As Os-
kin et al23 documented, minimal kidney size or lack of
visualization of a distal renal artery or nephrogram at pre-
operative angiography were not predictive of nonrecon-
structible renal anatomy.
After revascularization a significant improvement in BP
control and reduction in medication requirements was
achieved. It is well-recognized that renovascular hyperten-
sion is responsible for a greater degree of target organ
damage than is essential hypertension.24 Consequently,
when successful renal revascularization provides substantial
benefit in BP control, it should be expected to limit target
organ damage as well.25 The magnitude and duration of
this benefit is unknown, because previous reports of either
endovascular or open surgical techniques to treat TARAS
have restricted outcome analyses to hypertension control
only.10,12,15
In our series, revascularization to treat TARAS resulted
in successful retrieval of renal function, consistent with
what has been demonstrated by Dean et al26 in atheroscle-
rotic renal artery disease. A documented increase in esti-
mated GFR, lowering of mean SCr, and withdrawal of two
patients from hemodialysis occurred after renal revascular-
ization. The importance of improvement or stabilization of
renal function on survival is evident when one considers
that two of the three patients who died during the course of
this study had failed renal interventions, which ultimately
resulted in the need for hemodialysis. The effect of an
initially successful revascularization on subsequent renal
function and patient survival has been demonstrated by
Hansen et al27 for atherosclerotic renal artery disease.
The most dramatic and immediate responses to renal
revascularization occurred in patients with severe cardiac
dysfunction. Refractory, uncontrolled heart failure, which
was present in 16% of the patients reported by Keiffer et al14
and 7% in our series, responded immediately to successful
revascularization, and never recurred. This is similar to the
dramatic results of renal revascularization for “flash” pul-
monary edema and cardiovascular collapse due to renal
artery stenosis. Given the unique effects of angiotensin II
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of LVH and dysfunction,28 these dramatic responses are
not entirely unexpected. However, the subtler finding of
echocardiographic evidence of LVH regression was unex-
pected. LVH regression after successful revascularization to
treat TARAS has not been previously reported, but LVH
regression has been reported in patients with atheroscle-
rotic renal artery disease treated medically29 or with renal
revascularization.25 Our findings require further prospec-
tive validation, because echocardiographic data were col-
lected over more than two decades, and the technology and
diagnostic criteria have evolved considerably. These find-
ings and the prevalence of echocardiographic abnormalities
in this patient population have prompted us to perform
echocardiography routinely in the initial evaluation of
TARAS.
The specific effect of TARAS on survival has not been
reported, because most studies concerning patients with
TA have focused on brachiocephalic involvement. How-
ever, it is well known that severe hypertension is an inde-
pendent predictor of premature death and major adverse
events in patients with TA,2,30,31 with 5-year survival rates
less than 60%.30 Ishikawa31 demonstrated that the presence
of severe hypertension alone reduces the 10-year event-free
survival from 97% to 59%. This is in a patient population
consisting predominantly of women of childbearing age,
whose life expectancy should be 68 to 70 years.32 In
addition, renal dysfunction33 and LVH34 both indepen-
dently increase the risk for cardiovascular events and death
from all causes. Survival in today’s era of more sophisticated
medical management of hypertension has not been re-
ported for TARAS. This precludes a direct comparison of
survival between patients managed with revascularization
versus those medically managed. However, the actuarial
survival rates of 96% at 5 years and 80% at 10 years reported
in this series strongly suggest that the response of BP and of
renal and cardiac function to renal revascularization posi-
tively influenced survival.
In conclusion, TARAS is an often unrecognized clinical
entity that can result in life-threatening hypertensive and
cardiovascular events. Surgical revascularization with use of
bypass grafts or endovascular intervention for early ste-
notic, nonocclusive TARAS provides demonstrable im-
provements in BP, and renal and cardiac function. The
documented salutary clinical response on BP, and renal and
cardiac function after successful intervention positively in-
fluenced survival. This positive global response establishes
renal revascularization as a successful and durable interven-
tion for TARAS and a benchmark to which other therapies
should be compared.
We thank Linda Chang, PhD, for assistance with statis-
tical analyses.
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www.mosby.com/jvs.DISCUSSIONDr Linda Reilly (San Francisco, Calif). Thank you, Mr Chair-
man, members, and guests. I would like to thank the Society for
inviting me to discuss this paper, and I would like to thank the
authors for providing me a copy of the paper in a timely manner. I
would also like to thank them for the second version of the paper,
and I’d like to thank them for the third version of the paper. Of
course, I am just teasing a little bit, because my usual state of being
way behind protected me from doing anything with any of the first
two versions of the paper. As my sister, with whom I am sharing a
room, will tell you, I was doing this last night.
The authors have reported their results managing 27 patients
with renal artery stenosis related to Takaysu’s arteritis. I have a few
questions for the authors regarding study design, data, and their
conclusions.
You included in your study group eight patients who under-
went prior renal artery treatment that had failed, including three
who had undergone previous aortorenal bypass. Other than the
obvious benefit of having more patients in the report, why include
this group of people? The fact that they have already failed treat-
ment may actually bias your results. In light of that, can you tell us
if the subsequent six graft stenoses or occlusions correlated with
the prior treatment failure, or not?
Approximately half of your patients were on steroids at the
time of the intervention for their Takaysu’s-induced renal artery
stenosis. Did the subsequent six graft failures correlate with steroid
use at the time of your intervention, or not?
Because these patients were accumulated over a long time
interval, I assume that this is a retrospective study. So how many of
these patients actually had creatinine clearance measurements?
Also, how many underwent transthoracic echocardiography to
establish the presence or absence of left ventricular hypertrophy
and its resolution?
I am also intrigued by the observation that two patients
developed left ventricular hypertrophy during follow-up. I wonder
if you have some comments on why that happened.
You report that both duplex ultrasound and MRA were used
for postoperative surveillance, but to the best of my recollection
neither of these modalities was available during the first several
years of your study, which began in 1977. Were you able to use anysurveillance modalities during that early time frame? If not, does
the lack of a surveillance instrument in the early part of the study
have any implication for your identification of end points, partic-
ularly graft stenosis or occlusion?
You suggest that an endoluminal approach to Takaysu’s-
induced renal artery stenosis might be appropriate in early circum-
stances, when the pathologic process is limited and somewhat
reversible. Could you characterize the stage for us in some manner
that would allow others to recognize it? Do you have information
about the interval between the onset of Takaysu’s disease in your
patients, or as a surrogate perhaps the point of diagnosis of
Takaysu’s in your patients, and the point at which you intervene for
the renal artery stenosis? This might possibly be used to guide
others in determining when endoluminal treatment might be
worth considering.
Based on the treatment outcomes, you conclude that surgical
renal revascularization is the primary intervention for patients with
Takaysu’s-related renal artery stenosis. Your results are certainly
quite laudable, and I don’t disagree with your view about the role
of operative renal revascularization in this condition. However, I
am not sure that your data can actually prove that point, particu-
larly in view of the lack of a comparison group of patients managed
with endoluminal techniques. It is important to realize that this
group of 27 patients was accumulated over 26 years, or 1 patient
per year. During that time both operative renal artery reconstruc-
tion and endoluminal reconstruction have evolved. Furthermore,
since many of the renal arteries treated in this series were occluded,
I think it amounted to approximately one third, the endoluminal
approach was likely not really an option for many of these patients.
So I would come to a different conclusion. I would conclude that
the exact role of each treatment approach remains to be defined,
with the debate centering on the areas of durability versus reduced
risk.
Again, I would like to thank the Society for the opportunity to
discuss the paper.
Dr Fred A. Weaver. Thank you, Dr Reilly. Hopefully I
captured all of those questions.
As far as the patients who had previously thrombosed aorto-
renal bypasses, these were all procedures done at an outside insti-
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bypass did not correlate with any subsequent failure or stenoses in
our own group. There was no relation to the use of steroids or lack
of steroids or immunosuppression and graft failure. Our own bias
with regard to steroids and immunosuppressants is that it is a
modality to slow the disease progression. As we mention in the
article, our concept of the natural history of this disease is that it is
a one-time event, in which segments of the aorta are affected. They
then go on to develop an inflammatory process that over the course
of time develops into lesions and then occlusive lesions. There may
be superimposed atherosclerosis, as well, in the late stages of the
disease. But the disease is not one that over time involves new
segments previously not affected by the initial event. Conse-
quently, steroids and immunsuppressants are used to manage the
ongoing inflammatory response in those affected segments. Since
we attempt, as mentioned in the article, to place all of our anasto-
moses in uninvolved aorta, aortic graft, and/or the distal renal
artery, the immunosuppressive management may have little or no
effect on the vascular reconstructions. That also explains why we
had so many branch renal artery reconstructions, because, in order
to find normal renal artery, dissection beyond the main renal artery
was common.
All of the creatinine clearance was an estimated GFR based on
height, weight, and serum creatinine at the time of preoperative
evaluation and follow-up.
We had data on 21 patients with echocardiography and sub-
sequent echo follow-up, and that’s where the regression data come
from. It is admittedly a soft finding, and we mention this in the
article, because the techniques of echocardiography, as well as
diagnostic criteria, have evolved considerably over the time of this
study.
With regard to follow-up, it is true that duplex or MRA
modalities were not available. Any surveillance was performed
based on clinical findings and angiography. There was one patient
operated on in 1977, another patient in the early 1980s, and the
remaining patients were from the mid-1980s and on, when duplex
ultrasound scanning as well as early MRA were available at our
institution.
With regard to the role of endovascular therapy, I think the
one patient who we used who primarily was treated in this manner
is a good example of how it should be employed. This patient had
a febrile prodromal viral-type illness, and then about 2 years later
began to develop evidence of renal artery stenosis as well as
infrarenal aortic stenosis. It was at that time that she had interven-
tion in one renal artery, and then subsequently 1 year later in the
other renal artery, and throughout that period of time was main-
tained on steroids initially, and then methotrexate and cytoxan
immunosuppression subsequently. That patient has not developed
restenosis, and we have follow-up on her of 8 years. I fully expect
that over the course of time she most likely will require formal
surgical revascularization as the process continues in her renal
arteries. There is also no data in the literature at all on the use of
stents and whether in fact they might help in the outcome of
endovascular therapy.
I would agree that our data are not a straightforward compar-
ison, and given the infrequency of this disease and the rarity of
reports, not only in the United States but in the world in general,
comparison prospective studies are not going to happen. We havesubstantial experience in other vascular beds in Takaysu’s, and we
have found that surgical reconstruction works in our hands much
better than endovascular interventions, which we have used in
other beds as well.
I would like to thank Dr Reilly for the questions, and would be
happy to answer any other questions you might have.
Dr Louis Messina (San Francisco, Calif). Fred, I would like to
compliment you and your colleagues on another really excellent
publication in patients with Takaysu’s arteritis. I have two ques-
tions for you.
One, Takayasu’s is a clinical diagnosis, and so I was wondering
how many of your patients had arch or pulmonary artery involve-
ment, or how is it that you reach the diagnosis? As you know,
histologically they show giant cell infiltration, which makes it
difficult to distinguish from arteritis, so I would just appreciate
more information in that regard.
And then you did show an illustration of a patient who clearly
had visceral disease. Did any of your patients have symptomatic
visceral disease or disease that you thought required treatment?
How many did you treat, and in what way did you treat them?
Dr Weaver. With regard to the visceral artery disease, I would
say about a third of patients had concomitant visceral artery disease
of at least either the celiac or SMA. Our approach to revasculariza-
tion has been that, if they have no clinical symptoms, for example,
weight loss, abdominal pain, and so on and so forth, and in the
operating room they have a pulse in the small bowel mesentery, we
do not perform a prophylactic revascularization. On the other
hand, in those patients who do have visceral disease and are
symptomatic, we obviously will perform a revascularization. We
did that in one patient. A second patient had to be taken back to
the operating room and an aorta-SMA bypass performed, because
she developed mesenteric ischemia postoperatively. I will say, I
violated one of my premises in the operating room in the sense that
her SMA pulse after revascularization really was not so strong as it
should have been. I should have done it at the initial operation.
With regard to the diagnosis, you are absolutely right. It is a
clinical diagnosis, and we relied on the American College of
Rheumatology criteria. Predominantly, patients are female. They
are young. In our group, about half of them had brachiocephalic
disease. We had two patients with pulmonary artery disease, and we
had 13 patients or so for whom we had actual biopsy specimens
demonstrating an inflammatory arteritis. But, as you have well said,
it is a very nonspecific finding, and you cannot base the diagnosis
on histologic findings at operation.
Dr Ronald Dalman (Palo Alto, Calif). Fred, how did you
manage the oversewn aneurysm in the thoracic aorta?
Dr Weaver. We basically cross-clamped proximal, put our
graft in, just opened up that thrombosed aneurysm, left it in place,
oversewed distally, and then put the grafts in.
Dr Dennis Baker (Los Angeles, Calif). Do you have a stan-
dardized approach to decide whether you are going to use saphe-
nous vein or prosthetic for your bypass, because I see you have a
mix of the two?
Dr Weaver. That’s a good question. There are no data in the
literature as to which is preferable, prosthetic or saphenous vein. I
am beginning to move to the point where I think a prosthetic graft
may be a better choice, as long as it is a short-segment graft. I think
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not behave as well. I am a little reticent to do that if I have good
saphenous vein available.
Dr Charles Andersen (Tacoma, Wash). I question medical
treatment, surgical treatment, and the timing between the two. Do
you feel it is important to have the inflammatory component of the
disease under somewhat of a controlled state prior to surgical
intervention, and likewise in the postoperative course, to prevent
restenosis do you feel it is important to keep that inflammatory
component under control?
Dr Weaver. Well, the short answer is no, because the clinical
estimation of the inflammatory process is very inexact. You cannot
rely on ESR. In fact, in our earlier study back in the 1980s webetween the amount of inflammatory process on the biopsy spec-
imens and the degree of ESR. So we do not make any attempt to
bring the ESR down with immunosuppression to less than 20 or
so. All that does is delay a necessary operation.
With regard to postoperative treatment, as I mentioned, we
make every effort, and it is actually absolutely essential for the
patency of these grafts to sew into proximal and distal vessels that
are uninvolved. Consequently the immunosuppression and ste-
roids are not used to prevent graft failure. It was not recurrent
Takaysu’s arteritis in the two patients in whom we had histologic
specimens to review; the pathologic finding was intimal hyperpla-
sia. The long-term steroid use is to prevent the progression of the
disease in other segments that may have TA involvement, such ascompared biopsy specimens with ESR, and found no correlation the brachiocephalic and visceral vessels.
